Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tomohiro Iida

Showing results (201-210 of 219) with videos related to

Pageof 22
Sort By:
Progress in Retinal and Eye Research|May 24, 2021
Venous overload choroidopathy: A hypothetical framework for central serous chorioretinopathy and allied disordersRichard F Spaide, Chui Ming Gemmy Cheung, Hidetaka Matsumoto, et al.
Japanese Journal of Ophthalmology|December 26, 2025
Intravitreal aflibercept 8 mg in patients from Japan with neovascular age-related macular degeneration: 48-week subgroup analysis of the PULSAR trialHideki Koizumi, Shigeru Honda, Tsutomu Yasukawa, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|September 5, 2023
Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degenerationKeiko Kataoka, Kanako Itagaki, Nozumu Hashiya, et al.
Ophthalmology|September 5, 2015
MMP20 and ARMS2/HTRA1 Are Associated with Neovascular Lesion Size in Age-Related Macular DegenerationYumiko Akagi-Kurashige, Kenji Yamashiro, Norimoto Gotoh, et al.
Scientific Reports|May 22, 2024
One-year outcomes and safety assessment of faricimab in treatment-naïve patients with neovascular age-related macular degeneration in JapanRyo Mukai, Keiko Kataoka, Koji Tanaka, et al.
Plos One|March 7, 2020
Five-year follow-up of fundus autofluorescence and retinal sensitivity in the fellow eye in exudative age-related macular degeneration in JapanAri Shinojima, Miki Sawa, Ryusaburo Mori, et al.
Scientific Reports|May 30, 2023
Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in JapanRyo Mukai, Keiko Kataoka, Koji Tanaka, et al.
Plos One|March 1, 2019
Fundus autofluorescence and retinal sensitivity in fellow eyes of age-related macular degeneration in JapanTsutomu Yasukawa, Ryusaburo Mori, Miki Sawa, et al.
Japanese Journal of Ophthalmology|May 20, 2022
Short-term results for brolucizumab in treatment-naïve neovascular age-related macular degeneration: a Japanese multicenter studyKoji Tanaka, Hideki Koizumi, Tamaki Tamashiro, et al.
Ophthalmology|February 21, 2024
TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2Arshad M Khanani, Aachal Kotecha, Andrew Chang, et al.
Pageof 22

Showing results (201-210 of 219) with videos related to

Sort By:
Pageof 22
Progress in Retinal and Eye Research|May 24, 2021
Venous overload choroidopathy: A hypothetical framework for central serous chorioretinopathy and allied disordersRichard F Spaide, Chui Ming Gemmy Cheung, Hidetaka Matsumoto, et al.
Japanese Journal of Ophthalmology|December 26, 2025
Intravitreal aflibercept 8 mg in patients from Japan with neovascular age-related macular degeneration: 48-week subgroup analysis of the PULSAR trialHideki Koizumi, Shigeru Honda, Tsutomu Yasukawa, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|September 5, 2023
Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degenerationKeiko Kataoka, Kanako Itagaki, Nozumu Hashiya, et al.
Ophthalmology|September 5, 2015
MMP20 and ARMS2/HTRA1 Are Associated with Neovascular Lesion Size in Age-Related Macular DegenerationYumiko Akagi-Kurashige, Kenji Yamashiro, Norimoto Gotoh, et al.
Scientific Reports|May 22, 2024
One-year outcomes and safety assessment of faricimab in treatment-naïve patients with neovascular age-related macular degeneration in JapanRyo Mukai, Keiko Kataoka, Koji Tanaka, et al.
Plos One|March 7, 2020
Five-year follow-up of fundus autofluorescence and retinal sensitivity in the fellow eye in exudative age-related macular degeneration in JapanAri Shinojima, Miki Sawa, Ryusaburo Mori, et al.
Scientific Reports|May 30, 2023
Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in JapanRyo Mukai, Keiko Kataoka, Koji Tanaka, et al.
Plos One|March 1, 2019
Fundus autofluorescence and retinal sensitivity in fellow eyes of age-related macular degeneration in JapanTsutomu Yasukawa, Ryusaburo Mori, Miki Sawa, et al.
Japanese Journal of Ophthalmology|May 20, 2022
Short-term results for brolucizumab in treatment-naïve neovascular age-related macular degeneration: a Japanese multicenter studyKoji Tanaka, Hideki Koizumi, Tamaki Tamashiro, et al.
Ophthalmology|February 21, 2024
TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2Arshad M Khanani, Aachal Kotecha, Andrew Chang, et al.
Pageof 22